Meredith M Regan
ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer
Leyland-Jones B, Maibach R, Price K, Coates A, Goldhirsch A, Gelber R, Pagani O, Viale G, Rae J, Regan M, Arnould L, Neven P, Harvey V, Gray K, Abramovitz M, Bouzyk M, Young B, Long B, Kammler R, Dell'Orto P, Biasi M, Thürlimann B, BIG 1-98 Collaborative Group. ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer. Breast Cancer Res Treat 2015; 154:543-55.
Nov 21, 2015ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer
Nov 21, 2015Breast Cancer Res Treat 2015; 154:543-55
Leyland-Jones Brian, Maibach Rudolf, Price Karen N, Coates Alan S, Goldhirsch Aron, Gelber Richard D, Pagani Olivia, Viale Giuseppe, Rae James M, Regan Meredith M, Arnould Laurent, Neven Patrick, Harvey Vernon, Gray Kathryn P, Abramovitz Mark, Bouzyk Mark, Young Brandon, Long Bradley, Kammler Roswitha, Dell'Orto Patrizia, Biasi Maria Olivia, Thürlimann Beat, BIG 1-98 Collaborative Group
Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials
Regan M, Sessa F, Peg Cámara V, Rodríguez Peralto J, MacGrogan G, Colleoni M, Goldhirsch A, Price K, Coates A, Gelber R, Viale G, Öhlschlegel C, Pizzolitto S, Pagani O, Francis P, Fleming G, Walley B, Kammler R, Dell'Orto P, Russo L, Szőke J, Doimi F, Villani L, SOFT and TEXT Investigators and International Breast Cancer Study Group. Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials. Breast Cancer Res Treat 2015
Oct 22, 2015Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials
Oct 22, 2015Breast Cancer Res Treat 2015
Regan Meredith M, Sessa Fausto, Peg Cámara Vicente, Rodríguez Peralto José Luis, MacGrogan Gaëtan, Colleoni Marco, Goldhirsch Aron, Price Karen N, Coates Alan S, Gelber Richard D, Viale Giuseppe, Öhlschlegel Christian, Pizzolitto Stefano, Pagani Olivia, Francis Prudence A, Fleming Gini F, Walley Barbara A, Kammler Roswitha, Dell'Orto Patrizia, Russo Leila, Szőke János, Doimi Franco, Villani Laura, SOFT and TEXT Investigators and International Breast Cancer Study Group
Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial
Metzger Filho O, Coates A, Regan M, Price K, Debled M, Ejlertsen B, Colleoni M, Gelber R, Thürlimann B, Winer E, Viale G, Gusterson B, Mallon E, Giobbie-Hurder A, Goldhirsch A. Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial. J Clin Oncol 2015; 33:2772-9.
Jul 27, 2015Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial
Jul 27, 2015J Clin Oncol 2015; 33:2772-9
Metzger Filho Otto, Coates Alan S, Regan Meredith M, Price Karen N, Debled Marc, Ejlertsen Bent, Colleoni Marco, Gelber Richard D, Thürlimann Beat, Winer Eric P, Viale Giuseppe, Gusterson Barry, Mallon Elizabeth, Giobbie-Hurder Anita, Goldhirsch Aron
Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials
Bernhard J, Regan M, Pagani O, Fleming G, Francis P, Price K, Coates A, Gelber R, Goldhirsch A, Parmar V, Pavesi L, Puglisi F, Luo W, Ribi K, Colleoni M, Burstein H, Tondini C, Pinotti G, Spazzapan S, Ruhstaller T, Walley B. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. Lancet Oncol 2015; 16:848-58.
Jun 16, 2015Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials
Jun 16, 2015Lancet Oncol 2015; 16:848-58
Bernhard Jürg, Regan Meredith M, Pagani Olivia, Fleming Gini F, Francis Prudence A, Price Karen N, Coates Alan S, Gelber Richard D, Goldhirsch Aron, Parmar Vani, Pavesi Lorenzo, Puglisi Fabio, Luo Weixiu, Ribi Karin, Colleoni Marco, Burstein Harold J, Tondini Carlo, Pinotti Graziella, Spazzapan Simon, Ruhstaller Thomas, Walley Barbara A
CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial
Leyland-Jones B, Neven P, Treilleux I, Rasmussen B, Maibach R, Price K, Coates A, Goldhirsch A, Pagani O, Viale G, Rae J, Harvey V, Ditzel H, Gray K, Abramovitz M, Bouzyk M, Young B, Long B, Kammler R, Dell'Orto P, Biasi M, Thürlimann B, Lyng M, Regan M. CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Breast Cancer Res Treat 2015; 151:373-84.
May 3, 2015CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial
May 3, 2015Breast Cancer Res Treat 2015; 151:373-84
Leyland-Jones Brian, Neven Patrick, Treilleux Isabelle, Rasmussen Birgitte Bruun, Maibach Rudolf, Price Karen N, Coates Alan S, Goldhirsch Aron, Pagani Olivia, Viale Giuseppe, Rae James M, Harvey Vernon J, Ditzel Henrik J, Gray Kathryn P, Abramovitz Mark, Bouzyk Mark, Young Brandon, Long Bradley, Kammler Roswitha, Dell'Orto Patrizia, Biasi Maria Olivia, Thürlimann Beat, Lyng Maria B, Regan Meredith M
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer
Pagani O, Winer E, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price K, Bernhard J, Luo W, Ribi K, Viale G, Coates A, Gelber R, Goldhirsch A, Francis P, TEXT and SOFT Investigators, Ruhstaller T, Crivellari D, Puglisi F, Regan M, Walley B, Fleming G, Colleoni M, Láng I, Gomez H, Tondini C, Burstein H, Perez E, Ciruelos E, Stearns V, Bonnefoi H, Martino S, Geyer C, Pinotti G, International Breast Cancer Study Group. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 2014; 371:107-18.
Jun 1, 2014Adjuvant exemestane with ovarian suppression in premenopausal breast cancer
Jun 1, 2014N Engl J Med 2014; 371:107-18
Pagani Olivia, Winer Eric P, Rabaglio-Poretti Manuela, Maibach Rudolf, Ruepp Barbara, Giobbie-Hurder Anita, Price Karen N, Bernhard Jürg, Luo Weixiu, Ribi Karin, Viale Giuseppe, Coates Alan S, Gelber Richard D, Goldhirsch Aron, Francis Prudence A, TEXT and SOFT Investigators, Ruhstaller Thomas, Crivellari Diana, Puglisi Fabio, Regan Meredith M, Walley Barbara A, Fleming Gini F, Colleoni Marco, Láng István, Gomez Henry L, Tondini Carlo, Burstein Harold J, Perez Edith A, Ciruelos Eva, Stearns Vered, Bonnefoi Hervé R, Martino Silvana, Geyer Charles E, Pinotti Graziella, International Breast Cancer Study Group
Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial
Ewertz M, Goldhirsch A, Coates A, Smith I, Láng I, Colleoni M, Gelber R, Rabaglio M, Paridaens R, Forbes J, Bonnefoi H, Thürlimann B, Price K, Ejlertsen B, Regan M, Gray K, Mouridsen H. Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial. J Clin Oncol 2012; 30:3967-75.
Oct 8, 2012Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial
Oct 8, 2012J Clin Oncol 2012; 30:3967-75
Ewertz Marianne, Goldhirsch Aron, Coates Alan S, Smith Ian E, Láng István, Colleoni Marco, Gelber Richard D, Rabaglio Manuela, Paridaens Robert J, Forbes John F, Bonnefoi Hervé, Thürlimann Beat, Price Karen N, Ejlertsen Bent, Regan Meredith M, Gray Kathryn P, Mouridsen Henning T
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial
Regan M, Debled M, Maibach R, Price K, Gelber R, Coates A, Goldhirsch A, Rae J, Viale G, Neven P, Ditzel H, Lyng M, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, Dell'Orto P, Biasi M, Thürlimann B, Breast International Group (BIG) 1-98 Collaborative Group. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst 2012; 104:441-51.
Mar 6, 2012CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial
Mar 6, 2012J Natl Cancer Inst 2012; 104:441-51
Regan Meredith M, Debled Marc, Maibach Rudolf, Price Karen N, Gelber Richard D, Coates Alan S, Goldhirsch Aron, Rae James M, Viale Giuseppe, Neven Patrick, Ditzel Henrik J, Lyng Maria B, Leyland-Jones Brian, Bouzyk Mark, Pagani Olivia, Tang Weining, Kammler Roswitha, Dell'Orto Patrizia, Biasi Maria Olivia, Thürlimann Beat, Breast International Group (BIG) 1-98 Collaborative Group
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up
Regan M, BIG 1-98 Collaborative Group, Thürlimann B, Coates A, Gelber R, Price K, Rabaglio M, Wardley A, Láng I, Smith I, Forbes J, Mauriac L, Ejlertsen B, Goldhirsch A, Giobbie-Hurder A, Neven P, International Breast Cancer Study Group (IBCSG). Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. Lancet Oncol 2011; 12:1101-8.
Oct 20, 2011Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up
Oct 20, 2011Lancet Oncol 2011; 12:1101-8
Regan Meredith M, BIG 1-98 Collaborative Group, Thürlimann Beat, Coates Alan S, Gelber Richard D, Price Karen N, Rabaglio Manuela, Wardley Andrew, Láng István, Smith Ian, Forbes John F, Mauriac Louis, Ejlertsen Bent, Goldhirsch Aron, Giobbie-Hurder Anita, Neven Patrick, International Breast Cancer Study Group (IBCSG)
The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause
Chirgwin J, Coates A, Goldhirsch A, Regan M, Bonnefoi H, Ejlertsen B, Thürlimann B, Price K, Smith I, Sun Z, BIG 1-98 Collaborative and International Breast Cancer Study Groups. The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause. Breast Cancer Res Treat 2011; 131:295-306.
Sep 4, 2011The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause
Sep 4, 2011Breast Cancer Res Treat 2011; 131:295-306
Chirgwin Jacquie, Coates Alan S, Goldhirsch Aron, Regan Meredith M, Bonnefoi Hervé, Ejlertsen Bent, Thürlimann Beat, Price Karen N, Smith Ian, Sun Zhuoxin, BIG 1-98 Collaborative and International Breast Cancer Study Groups
Interpreting breast international group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer
Regan M, Price K, Giobbie-Hurder A, Thürlimann B, Gelber R, for the International Breast Cancer Study Group and BIG 1-98 Collaborative Group. Interpreting breast international group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer. Breast Cancer Res 2011; 13:209.
May 26, 2011Interpreting breast international group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer
May 26, 2011Breast Cancer Res 2011; 13:209
Regan Meredith M, Price Karen N, Giobbie-Hurder Anita, Thürlimann Beat, Gelber Richard D, for the International Breast Cancer Study Group and BIG 1-98 Collaborative Group
Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study
Colleoni M, Coates A, Gelber R, Price K, Wardley A, Pienkowski T, Chirgwin J, Smith I, Láng I, Paridaens R, Forbes J, Mauriac L, Mouridsen H, Thürlimann B, Regan M, Giobbie-Hurder A, Goldhirsch A. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J Clin Oncol 2011; 29:1117-24.
Feb 14, 2011Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study
Feb 14, 2011J Clin Oncol 2011; 29:1117-24
Colleoni Marco, Coates Alan S, Gelber Richard D, Price Karen N, Wardley Andrew, Pienkowski Tadeusz, Chirgwin Jacquie, Smith Ian, Láng István, Paridaens Robert, Forbes John F, Mauriac Louis, Mouridsen Henning, Thürlimann Beat, Regan Meredith M, Giobbie-Hurder Anita, Goldhirsch Aron
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer
BIG 1-98 Collaborative Group, Gelber R, Regan M, Price K, Forbes J, Mauriac L, Smith I, Paridaens R, Thürlimann B, Goldhirsch A, Giobbie-Hurder A, Mouridsen H, Coates A. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. NEJM 2009; 361:766-76.
Aug 20, 2009Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer
Aug 20, 2009NEJM 2009; 361:766-76
BIG 1-98 Collaborative Group, Gelber Richard D, Regan Meredith M, Price Karen N, Forbes John F, Mauriac Louis, Smith Ian, Paridaens Robert, Thürlimann Beat, Goldhirsch Aron, Giobbie-Hurder Anita, Mouridsen Henning, Coates Alan S
Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole
Viale G, Olszewski W, Knox F, Thürlimann B, Price K, Castiglione-Gertsch M, Gelber R, Gusterson B, Goldhirsch A, Orosz Z, Neven P, Öhlschlegel C, Giobbie-Hurder A, Regan M, Coates A, Mastropasqua M, Dell'Orto P, Maiorano E, MacGrogan G, Braye S, Breast International Group Trial 1-98. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 2008; 26:5569-75.
Nov 3, 2008Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole
Nov 3, 2008J Clin Oncol 2008; 26:5569-75
Viale Giuseppe, Olszewski Wojciech P, Knox Fiona, Thürlimann Beat, Price Karen N, Castiglione-Gertsch Monica, Gelber Richard D, Gusterson Barry A, Goldhirsch Aron, Orosz Zsolt, Neven Patrick, Öhlschlegel Christian, Giobbie-Hurder Anita, Regan Meredith M, Coates Alan S, Mastropasqua Mauro G, Dell'Orto Patrizia, Maiorano Eugenio, MacGrogan Gaëtan, Braye Stephen G, Breast International Group Trial 1-98
Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group
Viale G, Gusterson B, Goldhirsch A, Price K, Castiglione-Gertsch M, Gelber R, Rusca T, Grigolato P, Braye S, Öhlschlegel C, Pillay K, Kovács A, Brown R, Perin T, Golouh R, Mastropasqua M, Maiorano E, Regan M, Coates A. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group. J Clin Oncol 2008; 26:1404-10.
Mar 20, 2008Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group
Mar 20, 2008J Clin Oncol 2008; 26:1404-10
Viale Giuseppe, Gusterson Barry A, Goldhirsch Aron, Price Karen N, Castiglione-Gertsch Monica, Gelber Richard D, Rusca Tiziana, Grigolato Piergiovanni, Braye Stephen, Öhlschlegel Christian, Pillay Komala, Kovács Anikó, Brown Robert W, Perin Tiziana, Golouh Rastko, Mastropasqua Mauro G, Maiorano Eugenio, Regan Meredith M, Coates Alan S
Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer
Viale G, Coates A, Goldhirsch A, Gelber R, Castiglione-Gertsch M, Gusterson B, Öhlschlegel C, Pillay K, Kovács A, Brown R, Perin T, Golouh R, Price K, Colleoni M, Maiorano E, Maffini F, Mastropasqua M, Regan M, International Breast Cancer Study Group. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst 2008; 100:207-12.
Jan 29, 2008Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer
Jan 29, 2008J Natl Cancer Inst 2008; 100:207-12
Viale Giuseppe, Coates Alan S, Goldhirsch Aron, Gelber Richard D, Castiglione-Gertsch Monica, Gusterson Barry A, Öhlschlegel Christian, Pillay Komala, Kovács Anikó, Brown R W, Perin Tiziana, Golouh Rastko, Price Karen N, Colleoni Marco, Maiorano Eugenio, Maffini Fausto, Mastropasqua Mauro G, Regan Meredith M, International Breast Cancer Study Group
Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial
Rasmussen B, Altermatt H, Gelber R, Castiglione-Gertsch M, Goldhirsch A, Gusterson B, Thürlimann B, Coates A, Viale G, Braye S, Lacroix-Triki M, Regan M, Lykkesfeldt A, Dell'Orto P, Del Curto B, Henriksen K, Mastropasqua M, Price K, Méry E, BIG 1-98 Collaborative and International Breast Cancer Study Groups. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. The Lancet 2008; 9:23-8.
Jan 1, 2008Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial
Jan 1, 2008The Lancet 2008; 9:23-8
Rasmussen Birgitte B, Altermatt Hans J, Gelber Richard D, Castiglione-Gertsch Monica, Goldhirsch Aron, Gusterson Barry A, Thürlimann Beat, Coates Alan S, Viale Giuseppe, Braye Stephen, Lacroix-Triki Magali, Regan Meredith M, Lykkesfeldt Anne E, Dell'Orto Patrizia, Del Curto Barbara, Henriksen Katrine L, Mastropasqua Mauro G, Price Karen N, Méry Eliane, BIG 1-98 Collaborative and International Breast Cancer Study Groups
Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98
Viale G, Gusterson B, Goldhirsch A, Price K, Castiglione-Gertsch M, Gelber R, Thürlimann B, Öhlschlegel C, Braye S, Orosz Z, Neven P, Raffoul J, Rasmussen B, Dell'Orto P, Mastropasqua M, Maiorano E, Regan M, Coates A. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 2007; 25:3846-52.
Aug 6, 2007Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98
Aug 6, 2007J Clin Oncol 2007; 25:3846-52
Viale Giuseppe, Gusterson Barry A, Goldhirsch Aron, Price Karen N, Castiglione-Gertsch Monica, Gelber Richard D, Thürlimann Beat, Öhlschlegel Christian, Braye Stephen, Orosz Zsolt, Neven Patrick, Raffoul Johnny, Rasmussen Birgitte Bruun, Dell'Orto Patrizia, Mastropasqua Mauro G, Maiorano Eugenio, Regan Meredith M, Coates Alan S